JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $80
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $77 to $80.
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $77 to $80.